Pretreatment serum albumin-to-alkaline phosphatase ratio is an independent prognosticator of survival in patients with metastatic gastric cancer

Table 2 Univariate and multivariate analyses of prognostic factors for overall survival for all patients

Variables	Univariate analyses		Multivariate analyses
	HR (95%CI)	P value	HR (95%CI)	P value
Gender (male vs female)	0.705 (0.510-0.975)	0.035	0.746 (0.508-1.094)	0.133
Age (> 60 vs ≤ 60)	1.125 (0.794-1.594)	0.509	0.808 (0.541-1.207)	0.298
Smoking status (Yes vs No)	1.451 (0.970-2.173)	0.070	1.364 (0.851-2.188)	0.197
Number of involved sites (multiple vs one)	1.748 (1.264-2.417)	0.001	1.425 (1.018-1.997)	0.038
Liver metastasis (Yes vs No)	0.950 (0.674-1.339)	0.731	0.758 (0.511-1.124)	0.167
Bone metastasis (Yes vs No)	1.319 (0.822-2.115)	0.251	1.395 (0.843-2.307)	0.195
Treatment regimens (combination chemotherapy vs others)	0.334 (0.232-0.480)	0.000	0.269 (0.175-0.411)	0.000
AAPR (> 0.48 vs ≤ 0.48)	0.536 (0.385-0.745)	0.000	0.476 (0.328-0.691)	0.000

HR: Hazard ratio; CI: Confidence interval; AAPR: Albumin-to-alkaline phosphatase ratio.